October 24, 2021

Q-VD-OPh hydrate

Q-VD-OPh hydrate 

To Order Contact us: bjorn@lembcke.dk

Q-VD-OPh hydrate

A1901-5 5 mg
EUR 398
Description: The broad spectrum caspase inhibitor, QVD-OPh, provides a cost effective, non toxic, and highly speci?c means of apoptotic inhibition and provides new insight into the design of new inhibitors1.

Q-VD-OPh hydrate

A1901-5.1 10 mM (in 1mL DMSO)
EUR 688
Description: The broad spectrum caspase inhibitor, QVD-OPh, provides a cost effective, non toxic, and highly speci?c means of apoptotic inhibition and provides new insight into the design of new inhibitors1.

Q-VD-OPh hydrate

A1901-S Evaluation Sample
EUR 81
Description: The broad spectrum caspase inhibitor, QVD-OPh, provides a cost effective, non toxic, and highly speci?c means of apoptotic inhibition and provides new insight into the design of new inhibitors1.

Q-VD-OPh hydrate

GK2336-1MG 1 mg
EUR 264

Q-VD-OPh hydrate

GK2336-5MG 5 mg
EUR 861

Q-VD-OPh

1170-1
EUR 234

Q-VD-OPh

1170-3
EUR 441

Q-VD-OPh

1170-5
EUR 729

Q-VD-OPh

1170-50 Ask for price

Q-VD-OPh

HY-12305 10mM/1mL
EUR 190

EZSolution? Q-VD-OPh

1173-1
EUR 207

Q-VD(OMe)-OPh

A8165-1 1 mg
EUR 177
Description: Q-VD-OPh (quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophenoxy]-methyl ketone) is a broad spectrum caspase inhibitor,  provides a cost effective, non toxic, and highly specific means of apoptotic inhibition and provides new insight into the design of new inhibitors.

Q-VD(OMe)-OPh

A8165-10 10 mg
EUR 630
Description: Q-VD-OPh (quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophenoxy]-methyl ketone) is a broad spectrum caspase inhibitor,  provides a cost effective, non toxic, and highly specific means of apoptotic inhibition and provides new insight into the design of new inhibitors.

Q-VD(OMe)-OPh

A8165-25 25 mg
EUR 978
Description: Q-VD-OPh (quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophenoxy]-methyl ketone) is a broad spectrum caspase inhibitor,  provides a cost effective, non toxic, and highly specific means of apoptotic inhibition and provides new insight into the design of new inhibitors.

Q-VD(OMe)-OPh

A8165-5 5 mg
EUR 398
Description: Q-VD-OPh (quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophenoxy]-methyl ketone) is a broad spectrum caspase inhibitor,  provides a cost effective, non toxic, and highly specific means of apoptotic inhibition and provides new insight into the design of new inhibitors.

Q-VD(OMe)-OPh

A8165-5.1 10 mM (in 1mL DMSO)
EUR 711
Description: Q-VD-OPh (quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophenoxy]-methyl ketone) is a broad spectrum caspase inhibitor,  provides a cost effective, non toxic, and highly specific means of apoptotic inhibition and provides new insight into the design of new inhibitors.

Q-VD(OMe)-OPh

A8165-S Evaluation Sample
EUR 81
Description: Q-VD-OPh (quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophenoxy]-methyl ketone) is a broad spectrum caspase inhibitor,  provides a cost effective, non toxic, and highly specific means of apoptotic inhibition and provides new insight into the design of new inhibitors.

(R)-Q-VD-OPh

HY-12305A 10mg
EUR 257

EZSolution? Q-VD-OPh, Negative Control

1174-1
EUR 207

Pan-caspase inhibitor, Q-VD(OMe)-OPh

2787-1
EUR 262

Pan-caspase inhibitor, Q-VD(OMe)-OPh

2787-5
EUR 805

Q-VE-Oph

GL5302-1MG 1 mg
EUR 252

EZSolution? Q-DEVD-OPh

1178-1
EUR 272

Caspase-3 Inhibitor Q-DEVD-OPh

1175-1
EUR 272

Caspase-3 Inhibitor Q-DEVD-OPh

1175-3
EUR 533

Caspase-3 Inhibitor Q-DEVD-OPh

1175-5
EUR 805

Caspase-8 Inhibitor, Q-IETD-OPh

1176-1
EUR 305

Caspase-8 Inhibitor, Q-IETD-OPh

1176-3
EUR 686

Caspase-8 Inhibitor, Q-IETD-OPh

1176-5
EUR 990

Caspase-9 Inhibitor, Q-LEHD-OPh

1177-1
EUR 294

Caspase-9 Inhibitor, Q-LEHD-OPh

1177-3
EUR 675

Caspase-9 Inhibitor, Q-LEHD-OPh

1177-5
EUR 968

VD/ Rat VD ELISA Kit

ELA-E0917r 96 Tests
EUR 886

QVD-OPh Negative Control

1171-1
EUR 207

QVD-OPh Negative Control

1171-3
EUR 403

QVD-OPh Negative Control

1171-5
EUR 588

VD-PEG-NH2,2K

33-HE090005-2K
  • EUR 568.00
  • EUR 1591.00
  • 1g
  • 5g
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.

Human VD ELISA Kit

EHV0030 96Tests
EUR 521

Human VD ELISA Kit

EHV0033 96Tests
EUR 521

Bovine VD ELISA Kit

EBV0030 96Tests
EUR 521

Bovine VD ELISA Kit

EBV0033 96Tests
EUR 521

Anserini VD ELISA Kit

EAV0030 96Tests
EUR 521

Anserini VD ELISA Kit

EAV0033 96Tests
EUR 521

Chicken VD ELISA Kit

ECKV0030 96Tests
EUR 521

Canine VD ELISA Kit

ECV0030 96Tests
EUR 521

Canine VD ELISA Kit

ECV0033 96Tests
EUR 521

Goat VD ELISA Kit

EGTV0030 96Tests
EUR 521

Goat VD ELISA Kit

EGTV0033 96Tests
EUR 521

Sheep VD ELISA Kit

ESV0030 96Tests
EUR 521

Porcine VD ELISA Kit

EPV0030 96Tests
EUR 521

Porcine VD ELISA Kit

EPV0033 96Tests
EUR 521

Rabbit VD ELISA Kit

ERTV0030 96Tests
EUR 521

Rabbit VD ELISA Kit

ERTV0033 96Tests
EUR 521

Rat VD ELISA Kit

ERV0030 96Tests
EUR 521

Rat VD ELISA Kit

ERV0033 96Tests
EUR 521

Monkey VD ELISA Kit

EMKV0030 96Tests
EUR 521

Mouse VD ELISA Kit

EMV0030 96Tests
EUR 521

Mouse VD ELISA Kit

EMV0033 96Tests
EUR 521

Horse Vitamin D(VD)

QY-E120083 96T
EUR 478

Bosentan Hydrate

B1521-100 100 mg
EUR 212
Description: IC50: Inhibiting endothelin receptor A and B with an IC50 of 15.1 ± 1.6 ?M in P388/dx cells.A sulfonamide-derived, competitive and specific endothelin receptor antagonist with a relatively higher affinity to the endothelin A receptor than endothelin B receptor.

Bosentan Hydrate

B1521-200 200 mg
EUR 305
Description: IC50: Inhibiting endothelin receptor A and B with an IC50 of 15.1 ± 1.6 ?M in P388/dx cells.A sulfonamide-derived, competitive and specific endothelin receptor antagonist with a relatively higher affinity to the endothelin A receptor than endothelin B receptor.

Bosentan Hydrate

B1521-5.1 10 mM (in 1mL DMSO)
EUR 125
Description: IC50: Inhibiting endothelin receptor A and B with an IC50 of 15.1 ± 1.6 ?M in P388/dx cells.A sulfonamide-derived, competitive and specific endothelin receptor antagonist with a relatively higher affinity to the endothelin A receptor than endothelin B receptor.

Bosentan Hydrate

B1521-50 50 mg
EUR 142
Description: IC50: Inhibiting endothelin receptor A and B with an IC50 of 15.1 ± 1.6 ?M in P388/dx cells.A sulfonamide-derived, competitive and specific endothelin receptor antagonist with a relatively higher affinity to the endothelin A receptor than endothelin B receptor.

Bosentan Hydrate

B1521-500 500 mg
EUR 572
Description: IC50: Inhibiting endothelin receptor A and B with an IC50 of 15.1 ± 1.6 ?M in P388/dx cells.A sulfonamide-derived, competitive and specific endothelin receptor antagonist with a relatively higher affinity to the endothelin A receptor than endothelin B receptor.

Cephalexin Hydrate

B1522-25G
EUR 327

Cephalexin Hydrate

B1522-5G
EUR 120

Amikacin hydrate

B1657-50 50 mg
EUR 186
Description: Amikacin is an aminoglycoside antibiotic used to treat different types of bacterial infections.

Cefprozil hydrate

B2142-10 10 mg
EUR 309
Description: Cefprozil hydrate

Cefprozil hydrate

B2142-5 5 mg
EUR 187
Description: Cefprozil hydrate

Cefprozil hydrate

B2142-50 50 mg
EUR 837
Description: Cefprozil hydrate

Sitafloxacin Hydrate

B2150-10 10 mg
EUR 309
Description: Sitafloxacin Hydrate

Sitafloxacin Hydrate

B2150-5 5 mg
EUR 187
Description: Sitafloxacin Hydrate

Sitafloxacin Hydrate

B2150-5.1 10 mM (in 1mL DMSO)
EUR 247
Description: Sitafloxacin Hydrate

Sitafloxacin Hydrate

B2150-50 50 mg
EUR 837
Description: Sitafloxacin Hydrate

Sitafloxacin Hydrate

B2150-S Evaluation Sample
EUR 81
Description: Sitafloxacin Hydrate

Methylstat (hydrate)

B2836-1
EUR 142

Methylstat (hydrate)

B2836-5
EUR 370

Guanosine Hydrate

B3678-200 200 mg
EUR 142

Felbamate hydrate

B1145-10 10 mg
EUR 139
Description: Felbamate hydrate (FBM) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA) .

Felbamate hydrate

B1145-50 50 mg
EUR 357
Description: Felbamate hydrate (FBM) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA) .

Posaconazole hydrate

B1225-10 10 mg
EUR 215
Description: Posaconazole is a broad-spectrum, second generation, triazole compound with antifungal activity. Posaconazole strongly inhibits 14-alpha demethylase, a cytochrome P450-dependent enzyme

Posaconazole hydrate

B1225-5 5 mg
EUR 192
Description: Posaconazole is a broad-spectrum, second generation, triazole compound with antifungal activity. Posaconazole strongly inhibits 14-alpha demethylase, a cytochrome P450-dependent enzyme

Fluconazole hydrate

B1226-100 100 mg
EUR 96
Description: Fluconazole (hydrate) is a triazole antifungal drug used in the treatment and prevention of superficial and systemic fungal infections.

Fluconazole hydrate

B1226-1000 1 g
EUR 108
Description: Fluconazole (hydrate) is a triazole antifungal drug used in the treatment and prevention of superficial and systemic fungal infections.

Fluconazole hydrate

B1226-5.1 10 mM (in 1mL DMSO)
EUR 108
Description: Fluconazole (hydrate) is a triazole antifungal drug used in the treatment and prevention of superficial and systemic fungal infections.

Fluconazole hydrate

B1226-5000 5 g
EUR 224
Description: Fluconazole (hydrate) is a triazole antifungal drug used in the treatment and prevention of superficial and systemic fungal infections.

Stevioside hydrate

B1242-25
EUR 359

Stevioside hydrate

B1242-5
EUR 131

Tenofovir hydrate

B1252-10 10 mg
EUR 155
Description: Tenofovir hydrate is an inhibitor of reverse transcriptase used for the treatment of the human immunodeficiency virus 1(HIV-1) and hepatitis B [1].Tenofovir hydrate is an antiviral pro-drug and the class of nucleoside reverse transcriptase inhibitor.

Q-VD-OPh hydrate